Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)

被引：55

作者：

Haynes, Richard ^{[1
,2
]}

Staplin, Natalie ^{[1
,2
]}

Emberson, Jonathan ^{[1
,2
]}

Herrington, William G. ^{[1
,2
]}

Tomson, Charles ^{[3
]}

Agodoa, Lawrence ^{[4
]}

Tesar, Vladimir ^{[5
,6
]}

Levin, Adeera ^{[7
]}

Lewis, David ^{[1
,2
]}

Reith, Christina ^{[1
,2
]}

Baigent, Colin ^{[1
,2
]}

Landray, Martin J. ^{[1
,2
]}

机构：

[1] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England

[2] Univ Oxford, Nuffield Dept Populat Hlth, Epidemiol Studies Unit, Oxford, England

[3] North Bristol NHS Trust, Bristol, Avon, England

[4] NIDDK, NIH, Bethesda, MD 20892 USA

[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[6] Charles Univ Prague, Gen Univ Hosp, Prague, Czech Republic

[7] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2014年 / 64卷 / 01期

基金：

英国医学研究理事会;

关键词：

Kidney disease etiology; disease trajectory; end-stage renal disease (ESRD); disease progression; prognosis; cystic kidney disease; risk factor; PROGRESSION; FAILURE; ALBUMINURIA; PROTEINURIA;

D O I：

10.1053/j.ajkd.2013.12.013

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background: The relevance of the cause of kidney disease to prognosis among patients with chronic kidney disease is uncertain. Study Design: Observational study. Settings & Participants: 6,245 nondialysis participants in the Study of Heart and Renal Protection (SHARP). Predictor: Baseline cause of kidney disease was categorized into 4 groups: cystic kidney disease, diabetic nephropathy, glomerulonephritis, and other recorded diagnoses. Outcomes: End-stage renal disease (ESRD; dialysis or transplantation) and death. Results: During an average 4.7 years' follow-up, 2,080 participants progressed to ESRD, including 454 with cystic kidney disease (23% per year), 378 with glomerulonephritis (10% per year), 309 with diabetic nephropathy (12% per year), and 939 with other recorded diagnoses (8% per year). By comparison with patients with cystic kidney disease, other disease groups had substantially lower adjusted risks of ESRD (relative risks of 0.28 [95% CI, 0.24-0.32], 0.40 [95% CI, 0.34-0.47], and 0.29 [95% CI, 0.25-0.32] for glomerulonephritis, diabetic nephropathy, and other recorded diagnoses, respectively). Albuminuria and baseline estimated glomerular filtration rate were associated more weakly with risk of ESRD in patients with cystic kidney disease than the 3 other diagnostic categories (P for interaction, <0.001 and 0.01, respectively). Death before ESRD was uncommon in patients with cystic kidney disease, but was a major competing risk for participants with diabetic nephropathy, whose adjusted risk of death was 2-fold higher than that of the cystic kidney disease group (relative risk, 2.35 [95% CI, 1.73-3.18]). Limitations: Exclusion of patients with prior myocardial infarction or coronary revascularization. Conclusions: The cause of kidney disease has substantial prognostic implications. Other things being equal, patients with cystic kidney disease are at much higher risk of ESRD (and much lower risk of death before ESRD) than other patients. Patients with diabetic nephropathy are at particularly high risk of death prior to reaching ESRD. (C) 2014 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

引用

页码：40 / 48

页数：9